Lilly Diabetes President Enrique Conterno says a recent $1 billion investment in insulin manufacturing, half of which is in central Indiana, is paying off. Conterno says the unit is making inroads in major global markets, including China and Japan.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}